A current view on dopamine receptor agonists in the treatment of Parkinson’s disease

Nv, Titova

doi:10.17116/jnevro20151159176-83

Cited by 1 publication

(1 citation statement)

References 80 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dopamine agonists (such as pramipexole) 85 , 108 – 110 , monoamine oxidase B (MAOB) inhibitors (such as selegiline, rasagiline) 111 – 113 , and catechol-O-methyltransferase (COMT) inhibitors (such as entacapone, tolcapone) 85 , 114 were also reported to alleviate tremor via different mechanisms. It is easy to understand that COMT inhibitors alleviate tremor by promoting the effect of levodopa 85 , 114 .…”

Section: Introductionmentioning

confidence: 99%

A review on pathology, mechanism, and therapy for cerebellum and tremor in Parkinson’s disease

Zhong

Liu

et al. 2022

npj Parkinsons Dis.

View full text Add to dashboard Cite

Tremor is one of the core symptoms of Parkinson’s disease (PD), but its mechanism is poorly understood. The cerebellum is a growing focus in PD-related researches and is reported to play an important role in tremor in PD. The cerebellum may participate in the modulation of tremor amplitude via cerebello-thalamo-cortical circuits. The cerebellar excitatory projections to the ventral intermediate nucleus of the thalamus may be enhanced due to PD-related changes, including dopaminergic/non-dopaminergic system abnormality, white matter damage, and deep nuclei impairment, which may contribute to dysregulation and resistance to levodopa of tremor. This review summarized the pathological, structural, and functional changes of the cerebellum in PD and discussed the role of the cerebellum in PD-related tremor, aiming to provide an overview of the cerebellum-related mechanism of tremor in PD.

show abstract